Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 9

Results For "stable"

254 News Found

Gland Pharma reports Q2 FY26 PAT higher at Rs. 184 Cr
News | November 04, 2025

Gland Pharma reports Q2 FY26 PAT higher at Rs. 184 Cr

Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal


Orion secures license to Abzena’s next-generation cancer antibody
R&D | October 29, 2025

Orion secures license to Abzena’s next-generation cancer antibody

The antibody was designed and developed at Abzena’s Cambridge, UK,


Lilly buys Adverum for its phase 3-stage eye disease gene therapy
Biotech | October 27, 2025

Lilly buys Adverum for its phase 3-stage eye disease gene therapy

Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose


AbbVie's Rinvoq beats Humira in key arthritis trial
Clinical Trials | October 22, 2025

AbbVie's Rinvoq beats Humira in key arthritis trial

The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor


Botanic Healthcare unveils PeptiGlow and LipoLush for beauty and wellness
Healthcare | October 11, 2025

Botanic Healthcare unveils PeptiGlow and LipoLush for beauty and wellness

PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration


Fujifilm Biotechnologies opens cell culture manufacturing site in North Carolina
Biotech | September 26, 2025

Fujifilm Biotechnologies opens cell culture manufacturing site in North Carolina

Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031


Teva unveils promising SOLARIS resultsfor Olanzapine LAI
Clinical Trials | September 23, 2025

Teva unveils promising SOLARIS resultsfor Olanzapine LAI

No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks


Senhwa Biosciences’ Pidnarulex joins forces with global PD-1 leaders to advance next-gen immunotherapy
Clinical Trials | September 16, 2025

Senhwa Biosciences’ Pidnarulex joins forces with global PD-1 leaders to advance next-gen immunotherapy

This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program


Evonik and Ethris partner to expand offerings for nucleic acid delivery
Biotech | September 10, 2025

Evonik and Ethris partner to expand offerings for nucleic acid delivery

Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support